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Glioblastoma (GBM) is one of the most aggressive forms of brain tumor. With the 
current standard of care, survival prognosis for GBM patients is 15 months with a five-year 
survival rate of less than 3%. An increased understanding of the molecular mechanisms 
leading to cell growth and survival of GBMs may result in novel treatments to target and 
eradicate the disease. The protein Basigin-2 (aka EMMPRIN) induces the expression of 
matrix metalloproteinase (MMP) enzymes, and its expression level is positively correlated 
with GBM tumor grade. In 2011, Liao et al. reported that a splice variant of the basigin gene, 
called Basigin-3, may have an inhibitory function when bound to Basigin-2 in Human 
Hepatocellular Carcinoma (HHC) cells, as it decreases tumor growth, invasion and MMP 
expression. The goal of this study is to determine the effects of Basigin-3 overexpression in 
GBM cell growth. For this a recombinant fusion protein consisting of Basigin-3 and the red 
fluorescent protein mKate2 was overexpressed in a GBM cell line (LN229). RT-PCR and RT-
qPCR was used to measure MMP gene expression in Basigin-3/mKate2 expressing cells, 
and confocal microscopy used to confirm over-expression of Basigin-3 in the transfected 
populations. Our hypothesis that Basigin-3 overexpression would reduce MMP expression 
cells was not supported by our data suggesting that Basigin-3 in GBM does not as an 
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LITERATURE REVIEW AND BACKGROUND 
 
INTRODUCTION TO GLIOBLASTOMA  
 
Glioblastoma (GBM) is the most aggressive and life threatening form of primary 
metastatic brain tumor in humans. GBMs makes up 17% of all brain tumors, 60-70% of all 
astrocytomas, and have an incidence of 6.04 per 100,000 people per year in the United 
States (Association, 2010).  Even with the use of standard treatment, the median survival 
rate for GBM  is only 12.5 to 15 months and the five-year survival rate is less than 3% 
(Shibahara et al., 2013; Stupp et al., 2009; Weller et al., 2009; Yang et al., 2013). Clearly, an 
improved understanding of the molecular mechanisms regulating cell growth and survival 
of GBMs is need and could lead to novel treatments used to target and eradicate the 
disease.  
GBM tumors are classified as gliomas; tumors that arise from the supporting cells of 
the central nervous system. More specifically, a GBM is a Grade IV astrocytoma, a tumor 
arising from astrocytes (Association, 2010).  Grade IV tumors are the most malignant and 
aggressive. This grading system was developed by the World Health Organization (WHO), 
and grade IV tumors are characterized by hypercellularity, pleomorphism (individual cells 
vary in shape and size), frequent mitosis, microvascular proliferation and necrotic tissues 
are found within the tumor  (Coons, 1996). There are many factors that can lead to the 
development of a malignant glioma including environmental, genetic, and other 
physiological factors, such as prior exposure to therapeutic doses of ionizing radiation and 
genetic predispositions including Li-Fraumeni syndrome, Neurofibromatiosis type 1 and 2, 
and tuberous sclerosis (Juratli, Schackert, & Krex, 2013).  
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TREATMENT OF GBM 
The standard treatment for GBM tumors is surgical resection, followed by combined 
radiation and chemotherapy with temozolomide. Even with this standard treatment nearly 
all GBMs recur after initial therapy. The median survival rate of a patient diagnosed with 
GBM is about 12.5 to 15 months with current standard of treatment (Weller et al., 2009).  A 
high rate of recurrence and few effective treatments are to blame for the low five-year 
survival rate of less than 3% (Stupp et al., 2009).   
Surgical resection effectively reduces the size of the tumor, however complete 
resection is not possible due to the invasive nature of the tumors. To maximize the extent 
of tumor resection, intraoperative brain mapping and MRI along with 5-aminolevulinic acid 
(5-ALA) derived tumor fluorescence for intraoperative identification of malignant glioma 
tissue is used in some countries (Juratli et al., 2013). 5-ALA is a natural substrate of the 
heme synthesis pathway in mammalian cells were it is metabolized to produce the 
intermediate compound called protoporphyrin-IX (PpIX). PpIX is normally converted to 
heme by inserting the ferrous iron through the ferrochelatase enzyme within the 
mitochondria.  In malignant tissue the amount of ferrochelatase is decreased and causes 
the accumulation of PpIX in cancer cells (Duffner F., 2005).  PpIX is a photoactive 
compound and its accumulation in tumor cells makes it possible to visualize the cancerous 
cells within the brain when exposed to violet-blue light. In this way, cancer cells can be 
visualized by their fluorescence allowing for more complete resection of the tumor. 
Patients are given 5-ALA orally to increase the amount of 5-ALA in their system. The use of 
the 5-ALA treatment during tumor resection is helpful in removing majority of the tumor. 
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Because GBMs are diffuse tumors this resection technique still may not remove all of the 
tumor cells and leaves the chance for tumor reoccurrence (Eljamel, Goodman, & Moseley, 
2008).  
Radiation therapy uses high-energy radiation to damage cellular DNA in order to 
induce cell death in rapidly growing cells. Radiation therapy has been shown to be effective 
in the treatment of GBMs and increases the median survival rate from five to nine months 
compared to surgery alone.  Glioma tumors are made up of a heterogeneous mixture of cell 
types, with some cells being more resistant to radiation therapy than others. Thus, after the 
full dosage of radiation has been applied, some of the tumor may still be present (Juratli et 
al., 2013).  Radiation therapy causes double strand DNA breaks. It is possible for these 
breaks to be repaired by non-homologous end joining and is prone to error. Unrepaired 
double strand breaks trigger apoptosis, explaining why radiation is used as a treatment to 
kill cancerous cells (Roos & Kaina, 2006).  
Chemotherapy is also used to treat various types of cancer by damaging the DNA in 
rapidly reproducing cells. The use of chemotherapeutics to treat GBMs has been difficult. 
Systemic chemotherapy approaches generally do not work for GBMs because the 
chemotherapeutic agents cannot pass the blood-brain or blood-tumor barrier (Juratli et al., 
2013). There are a few chemotherapy agents that can cross the blood brain barrier or can 
be administered during surgery. In addition, GBMs can accumulate mutations that allow 




There are two groups of chemicals that are used for chemotherapy and can cross the 
blood-brain barrier: alkylating agents and nitrosources (Juratli et al., 2013). The most 
widely used chemotherapy agent to treat GBMs is temozolomide (TMZ), an alkylating agent 
that is taken orally and can pass the blood brain barrier (Juratli et al., 2013; Lawrence  J. E., 
2015). TMZ is a prodrug and is converted into the active drug, 5-(3-methyltriazen-1-
yl)imidazo-4-carboximide (MTIC). MTIC methylates the DNA most commonly on the N7 
position of guanine and N3 position of adenine. The O6 position of guanine can be 
methylated as well but is less common. The addition of these methyl groups are toxic to the 
cell and will induce apoptosis if not repaired (Lawrence  J. E., 2015). Tumor resistance to 
alkylating agents is a clinical problem caused by an overexpression of DNA repair enzymes. 
Alkylating agents add chemical groups to DNA which inhibit the cell cycle and stops cell 
growth (Juratli et al., 2013). The MGMT protein repairs the DNA by removing the chemical 
group, for example this protein can remove the methyl groups added by MTIC repairing the 
altered amino acids making them no longer cytotoxic  (Juratli et al., 2013; Lawrence  J. E., 
2015). If the chemical group is left on the DNA and not repaired by the MGMT protein, the 
chemotherapy lesion induces cell apoptosis (Juratli et al., 2013). 
Nitrosources are used to induce the alkylation to inhibit DNA replication. 
Carmustine can cross the blood-brain barrier and it is also effective against malignant 
glioma cell lines in vitro. However, it is also very toxic which is why systemic treatment 
with carmustine is limited. Carmustine wafers are also a form of alkylating chemotherapy 
where the drug-impregnated wafers are placed directly into the tumor resection, usually 
placed during a second surgery after the original resection. Since the wafers are used in a 
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second surgery, this treatment is usually reserved for younger patients with resectable 
tumors (Juratli et al., 2013).   
CANCER 
Cancer is defined as a group of diseases that is characterized by unregulated cell 
growth, invasion, and spread of cells (Pecorino, 2012).  This change in cell growth and 
invasion can be caused by an accumulation of mutations within the genome as a result of a 
genetic disorder passed down from parent to progeny, exposure to environmental 
carcinogens, or by random mutations that occur throughout a person’s life. The most 
common mutations resulting in tumor formation are mutations to either proto-oncogenes 
or tumor suppressor genes. Proto-oncogenes have a normal role in controlling cell growth 
or differentiation. When proto-oncogenes experience mutations resulting in elevated 
activity of the gene product, they become ‘oncogenes’ which promote cell growth and the 
formation of cancer. Tumor suppressor genes code for genes that negatively regulate cell 
growth. When these genes are altered in tumor cells they are changed in a way that 
decreases or abolishes their function.  For a tumor to develop it usually is a result of the 
combination of multiple mutations but there are a few specific mutations that increase the 
chance of developing a tumor (Medicine, 1992).  Several examples of the types of mutations 
that can promote cancer formation are outlined on the following pages. 
Li-Fraumeni syndrome 1 is a rare autosomal dominant disorder that is 
characterized by an early onset of tumors. The most prevalent mutation associated with 
this syndrome is to the p53 gene on chromosome 17p13.1 (Bachinski, 2005). The p53 gene 
codes for a tumor suppressor protein called p53 which acts as a transcription factor for a 
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large number of genes whose gene products function in cellular growth arrest, DNA repair, 
apoptosis regulation, and anti-angiogenic proteins. When the p53 gene is mutated, like in 
Li-Fraumeni syndrome, the p53 protein loses its ability to act as a transcription factor for 
these genes. Without the function of the p53 protein there is a loss in cell growth control 
leading to an overall increase in cell proliferation. Li-Fraumeni syndrome is not the only 
instance where p53 is mutated. The mutation can occur spontaneously and is commonly 
found in many types of cancers, including GBMs (Weinburg, 2007).  In a review of the 
molecular alterations that occur within different GBMs Dunn et al. demonstrated that p53 
was mutated in 42% of the tumor samples. In this work they used the Cancer Genome Atlas 
Research Network to explore somatically mutated genes in GBMs (Dunn et al., 2012).   
GENETICS OF GBM 
Cancer is the product of many mutations and epigenetic modifications that build on 
each other (Weinburg, 2007). There are many signaling pathways that are altered in GBMs, 
including the WNT, Ras, and PI3K pathways as described above (Brems, 2009; Ferner, 
2007; Tee, Manning, Roux, Cantley, & Blenis, 2003). The modification of signaling pathways 
in GBMs makes the understanding and treatment of GBMs very difficult (Zhu et al., 2009). 
Like other cancers, GBMs result from various mutations that can alter gene expression 
within a cell. Some genes tend to be more commonly mutated than others, including the 
genes p53, NF1, PTEN, and EGFR (Dunn et al., 2012).  
Neurofibromatosis is also an autosomal dominant disorder within the NF1 gene. 
This gene codes for the protein neurofibromin that functions as a tumor suppressor by 
inhibiting the Ras and WNT pathways. Neurofibromin is normally found in neuroglial cells 
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such as schwann cells. Patients afflicted with neurofibromatosis produce decreased 
amounts of neurofibromin, thus allowing uncontrolled cell growth and the formation of 
tumors within the nervous system (Brems, 2009; Ferner, 2007). In a review of the 
molecular basis of GBMs, an analysis of tumors from the cancer Genome Atlas Network, 
NF1 is one of the genes most commonly found mutated in GBMs at 21% of the tumors 
analyzed (Dunn et al., 2012).  
Phosphatase and Tensin Homolog (PTEN) is a tumor suppressor gene that is found 
on chromosome 10p23 (S. I. P. Wang, J.; Li, J.; Bruce, J. N.; Cairns, P.; Sidransky, D.; and 
Parsons, R., 1997). A common mutation found in over 90% of primary GBMs is the 
hemizygous or homozygous deletion of the PTEN gene (Gont, 2013).  PTEN is a 
phosphatase enzyme that converts the second messenger molecule phosphatidylinositol 
3,4,5 triphosphate (PIP3) to its inactive precursor phosphatidylinositol 3,4 bisphosphate 
(PIP2).  As stated previously, the phosphoinositol-3-kinase (PI3K) signaling pathway 
regulates cell growth and proliferation by stimulating the formation of PIP3 in response to 
cell stimuli. Because The PI3K and PTEN enzymes have opposing functions, with the loss of 
PTEN increasing the production of PIP3 by PI3K. This results in increased cell survival and 
cell growth within GBM tumors (Gont, 2013; Pezzolesi, Zbuk, Waite, & Eng, 2007).  
Epithelial Growth Factor Receptor (EGFR) is located on chromosome 7p11.2 and is 
mutated in nearly 50% of all GBMs (Brennan et al., 2013; Dunn et al., 2012; K. Wang, 
Yamamoto, Chin, Werb, & Vu, 2004; Zhu et al., 2009). EGFR and its ligand have a variety of 
functions in normal cells that are altered in cancer. For example, the amplification of the 
EGFR gene resulting in multiple copies of the gene increases cell proliferation due to 
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increased expression of EGFR. Another common EGFR mutation is an in-frame deletion of 
exons 2-7. This deletion produces a protein product called EGFRvIII that functions as a 
ligand-independent receptor (Zhu et al., 2009). These GBM mutations initiate early tumor 
development, sustain tumor growth, promote tumor infiltration, and resistance to therapy 
(K. Wang et al., 2004; Zhu et al., 2009). 
Epigenetic alterations can also affect gene expression leading to GBM formation 
(Weinburg, 2007). An important epigenetic factor for the treatment of GBMs is DNA 
methylation.  DNA methylation is the addition of a methyl group to the cytosine base of 
double-stranded DNA. This covalent addition also recruits proteins that bind to the methyl-
cytosine group to alter the structure of the DNA (Alberts, 2008).  One example of this type 
of epigenetic alteration in GBMs is the methylation of the O6-methylguanine-DNA-
methyltransferase (MGMT) gene promoter region. MGMT promoter methylation prevents 
MGMT gene expression and thus blocks MGMT function. MGMT is a DNA repair protein that 
removes chemical adducts from the O6 position on guanine, and in doing so targets the 
MGMT protein for degradation. The silencing of this gene by promoter methylation results 
in a loss of MGMT gene expression preventing MGMT-mediated DNA repair. Because the 
MGMT enzyme functions to remove chemical adducts from DNA in response to alkylating 
chemotherapeutics, the silencing of this gene by methylation can increases the 
effectiveness of current chemotherapy treatments (Rivera et al., 2010).  This is a prime 
example of the kind of information generated by basic research that can be taken 
advantage of in the treatment of GBM tumors. 
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Cancer cells that accumulate mutations from various genetic or environmental 
factors can alter their local tumor microenvironment through the proteins they produce. In 
other words, the proteins that the tumor cells produce can affect surrounding cells to 
support tumor survival and growth. For example, cells can release proteins from the cell 
surface through microvesicles or the secretion of soluble proteins. Interestingly, cancer 
cells produce elevated levels of some proteins and can stimulate surrounding stromal 
(normal) cells to express additional factors to reduce environmental constraints allowing 
for proliferation and metastasis of the tumor (Biswas C., 1995; Tsai et al., 2013).  One 
example of a protein that can stimulate surrounding stromal cells is the cell surface 
glycoprotein basigin-2 (also called EMMPRIN). High-grade astrocytomas overexpress this 
protein and the expression level positively correlates with WHO grades for astrocytomas 
suggesting that the overexpression of this protein plays a role in the tumors increased 
ability to survive  (Tsai et al., 2013).  Furthermore, the release of basigin-2 from tumor cells 
stimulates the expression of MMP enzymes in the surrounding normal tissue. MMPs 
catalyze the degradation of the extracellular matrix within tissues allowing for the growth 
and metastasis of tumors. Developing an understanding of the mechanisms and molecules 
mediating tumor-stromal cell interactions is important in the development of treatments 
and diagnostic strategies for metastatic cancers(Belton, Chen, Mesquita, & Nowak, 2008). 
BASIGIN GENE  
 
The basigin gene produces four variants that belong to the immunoglobulin 
superfamily of cell surface glycoproteins.  Basigin is a pleiotrophic molecule which means 
that it is under control of a single gene but has several distinct and unrelated effects on the 
cell’s phenotype.  Basigin plays critical roles in spermatogenesis, lymphocyte activation, 
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and expression of monocarboxlyate transporters, however basigin’s best characterized 
function is its ability stimulate the expression of matrix metalloproteinases (MMPs) in 
stromal cells (Belton et al., 2008; Iacono, Brown, Greene, & Saouaf, 2007; Weidle, 2010).  
Basigin is known by other names such as Extracellular Matrix Metalloproteinase Inducer 
(EMMPRIN), M6 Leukocyte Activation Antigen (M6) and CD147 Antigen (CD147) 
(McKusick and Converse).  The basigin gene is found on Chromosome 19, the specific 
cytogenic location is 19p13.3 and the gene contains ten exons (McKusick and Converse).   
There are four basigin isoforms (basigin-1, -2, -3, and -4) that possess a shared 
cytoplasmic and transmembrane domain but vary in their extracellular domains (Belton et 
al., 2008; Iacono et al., 2007).  The best known and most common basigin protein is isoform 
2 (basigin-2 or EMMPRIN). The transcriptional regulation, expression profiles and 
functions that distinguish the isoforms from each other are not well known. The basigin-1 
transcript is found exclusively in the retina and is distinguished by possessing three 
immunoglobulin (Ig)-like domains in the extracellular portion of the protein. Basigin-2 is 
the predominant variant and is distinguished by having two Ig-like domains. Basigin-3 is a 
short isoform containing one Ig-like domain that interacts with the internalized basigin-2 
during receptor-mediated endocytosis in an unknown manner (Belton et al., 2008). Little is 
known about the function of isoforms-3 or -4, but studies using hepatocarcinoma cells 
suggest that basigin-3 might function as an inhibitor of basigin-2(Liao et al., 2011).  The 
basigin gene  is widely expressed in normal cells, although there has not been extensive 
studies on the functions of basigin isoform 3 and 4, there have been many functions 
associated with basigin-2. Basigin-2 is the most highly expressed isoform and has been 
shown to be involved in different cellular mechanisms such as inducing the expression of 
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MMP,  and the recruitment of monocarboxylic acid transporters (MCTs) and ABC 
transporters to the cell membrane (Bleau, Huse, & Holland, 2014; T., 2003).  
Matrix malloproteinases are enzymes that break down elements of the extracellular 
matrix such as collagen, laminin, and fibronectin. Matrix degradation enzymes are activated 
by three different control mechanisms: local activation, confinement by cell-surface 
receptors, and secretion of inhibitors. Local activation is the mechanism by which 
proteases are secreted as inactive precursors that can be activated locally when needed. 
This activation method is used for more specific MMPs. Some MMPs are less specific and 
are more likely to be activated by the confinement of cell-surface receptors. This 
mechanism confines the enzymes to more specific areas where it is needed (Alberts, 2008).  
 There are four MCT isoforms (MCT1-4) and they have been shown to catalyze the 
transport of monocarboxylates (lactate, pyruvate, acetoacetate) across the cell membrane 
(Kirk P., 2000).  The transport of monocarboxylates is very important for cell metabolism, 
especially the transport of lactic acid, an acidic byproduct of glycolysis, out of the cell (Kirk 
P., 2000; Le Floch et al., 2011). Glycolysis occurs in all cells and is most commonly used in 
hypoxic situations. Basigin-2 has been shown to be a chaperone for MCT1 and MCT4 to the 
cell membrane and is necessary for the function of these MCTs (Kirk P., 2000; Le Floch et 
al., 2011).   
 ABCG2 is a half-transporter of the G subfamily of ATP binding cassette (ABC) 
transporters (Bleau et al., 2014; Jin et al., 2009; Zhou et al., 2013). ABC transporters use 
ATP to transport small molecules across the membrane. This movement helps detoxify the 
cell of cytotoxic agents, including drugs used to induce cell death (Bleau et al., 2014). In 
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order for ABCG2 to be active it needs to form dimers or oligomers, which is where basigin-
2 comes in. There is evidence that basigin-2 co-localizes with ABCG2 and can regulate 
ABCG2’s dimerization this allows the transporter to become active (Zhou et al., 2013).  
ABCG2 is upregulated in many different tumor types and its ability to transport drugs out 
of the cell causes the cell to develop a multidrug resistance (Jin et al., 2009).  
 
BASIGIN FUNCTION IN CANCER 
 
MMPs are found in abundance at the boundary between the tumor and the 
surrounding stromal tissue. The stromal cells are stimulated to express and secrete MMPs 
into the tumor microenvironment by the tumor cells (Weinberg, 2007). The most abundant 
tumor-related MMPs are interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), 
stromelysin-3 (MMP-11), and gelatinase A (MMP-2) (Sameshima, 2000).   
Analysis of numerous tumors has revealed that the elevated expression of basigin in 
tumor cells is correlated with an increasingly aggressive tumor phenotype (lacono et al., 
2007).  This overexpression of basigin-2 sets in motion an increase in many of basigin-2’s 
functions in cell survival. An increase in basigin-2 has also shown an increase in MCT 
expression. The tumor microenvironment is hypoxic due to the rapid cell growth. The lack 
of available oxygen for the rapidly growing tumor cells cause them to rely on fermentative 
glycolysis to survive. Lactic acid is byproduct of this type of metabolism but the 
accumulation within the cell is toxic. The increase of MCTs raises the amount of lactic acid 
the cell can transport across the membrane increasing the cell’s chance of survival (Kirk P., 
2000; Le Floch et al., 2011).  
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 Cancer cells overexpress basigin-2 and shed microvesicles containing basigin 
proteins. This increase of basigin-2 increases the stimulation of MMPs and decreases 
physiological inhibitors in the extracellular matrix, allowing the tumor to metastasize 
(Belton et al., 2008; Iacono et al., 2007).  Basigin-2 forms a homo-oliomer, a prerequisite to 
become fully functional, to stimulate MMPs secretion from surrounding stromal cells (Liao 
et al., 2011). Basigin-3 has also shown increased expression in cancer cells but is not 
expressed as highly as basigin-2. In a study done by Liao et al. involving human 
hepatocellular carcinoma, cells that overexpressed basigin-2 grew at the highest rates 
where cells that over-expressed basigin-3 grew at the lowest. These results suggest that 
basigin-2 promotes proliferation in cancer cells while basigin-3 inhibits proliferation. In 
human hepatocellular carcinoma lines basigin-3 interacts with basigin-2 to form a hetero-
oligomer. This interaction may regulate basigin-2 stimulation of MMP (Liao et al., 2011).  
SUMMARY 
The mechanisms used by cancer cells to proliferate and metastasize are a result of 
accumulated genetic changes within the cancer cells and are not yet fully understood. 
Mutations in cancerous cells contribute to the production of abnormal amounts or 
functionally altered proteins which can change how the cell functions and interacts with its 
surrounding environment. Members of the basigin gene isoforms have be found to be 
overexpressed in different types of tumors, with basigin-2 (EMMPRIN) overexpression 
strongly correlated with tumor grade. One of its more studied functions is the ability to 
induce the expression and secretion of MMPs from surrounding tissues, promoting the 
ability of the tumor to grow and metastasize. The function of basigin-3 is not well known 
but there is evidence supporting that it plays a role in competitively binding to Basigin-2 
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inhibiting basigin-2’s role in stimulating MMP secretion and decreases proliferation. 
Studying the localization of basigin-3 expression within glioblastoma (GBM) tumors and 
the changes in expression of proteins associated with basigin-2 stimulation could lead into 




































OBJECTIVES AND HYPOTHESES 
 
The objective of this project was to study the effects of basigin-3 overexpression in 
GBM cell lines. The function of basigin-3 is not known, but there is evidence supporting its 
role in competitively binding to Basigin-2 and inhibiting basigin-2’s ability to stimulate 
MMP expression. Measuring the effects of basigin-3 overexpression within glioblastoma 
(GBM) cell lines would lead into more extensive studies of its functions and influences 
within cancer cells.  
 
Hypothesis: Basigin-3 overexpression in GBM cell lines will reduce MMP gene expression 
levels. 
Aim 1: Generate stably-transfected GBM cell lines expressing a basigin-3/mKate2 fusion 
protein. 
Aim 2: Demonstrate basigin-3 overexpression in GBM cell lines   





















All plasmids were purchased from Origene Technologies (Rockville, MD). The 
plasmids were transformed into DH5alpha E. coli competent cells according to standard 
procedures. The basigin-3, basigin-2, and mKate2 expression vectors were selected with 
ampicillin, and single bacterial colonies from each plate were selected and used to 
inoculate 5mL of LB broth for amplification. Subsequently, the 5mL cultures were used to 
inoculate 100mL LB broth cultures for large scale amplification. All cultures were grown in 
LB broth with ampicillin at 37°C on a shaker table at 200 RPM. Plasmids were purified from 
the bacterial cultures using Qiagen Plasmid mini and maxi kits (Valencia, CA). After 
purification, DNA concentration and purity were determined by UV spectrometry using a 
Nanodrop spectrophotometer (Thermo Fisher, Waltham MA). Restriction enzymes and 
agarose gel electrophoresis were used to verify plasmid identity. The restriction enzymes 
used for analysis of the plasmids were Mlu1 and AsisI. 
 
SUBCLONING OF BASIGIN-3 INTO MKATE2 EXPRESSION VECTOR 
 
The open reading frame (ORF) of basigin-3 was amplified using the high fidelity 
Phusion DNA polymerase purchased from ThermoFisher (Waltham MA). Primers were 
designed to generate novel restriction sites on the amplicon in order to preferentially clone 
the genes in correct orientation. Primer information can be found in Table 1. Once the gene 
inserts were amplified by PCR, the ends were digested with the appropriate restriction 
enzymes. The gene inserts were verified and purified by agarose gel electrophoresis. The 
digested PCR product band was excised from the agrose gel and purified using QIAquick gel 
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extraction kit from Qiagen (Valencia, CA). The mKate2 expression vector was digested 
using Mlu1 and Asis1 and was also purified through gel electrophoresis. The basigin-3 ORF 
was ligated into the mKate2 expression vector using New England BioLab’s Quick Ligation 
Kit (Cat. #M2200S). The ligation product was transformed into competent E. coli bacteria 
and incubated in 500μl of growth media for 45 minutes. The transformed bacteria were 
then plated on LB agar plates with ampicillin and incubated overnight at 37°C. Single 
colonies were chosen and amplified in 5mL of LB broth. Recombinant plasmids were 
purified using Qiagen plasmid mini kits (Valencia, CA).  The plasmids were verified for 




Human glioblastoma cell line LN229 was maintained in DMEM with 10% FBS at 
37°C degrees Celsius and 5% CO2 at 100% humidity. The human foreskin fibroblast line 
MSU1.1 was maintained in EMEM with 10% FBS at 37 degrees Celsius and 5% CO2 at 100% 
humidity. Both cell types were plated and maintained on 10cm culture dishes.  
 
TRANSFORMATION OF BASIGIN-3/MKATE2 RECOMBINANT FUSION VECTOR 
 
 The mKate2 expression vector and the basigin-3 mKate2 recombinant fusion vector 
were transformed into LN229 GBM cell line and the MSU1.1 fibroblast cell line using the 
Neon transfection system (ThermoFisher, Waltham MA). One confluent 10cm culture plate 
of each the LN229 and MSU1.1 was treated with trypsin and counted. The cells are diluted 
to the suggested cell density and the cells are loaded into the Neon system tips. The 
appropriate settings are programed into the Neon system and the electroporation takes 
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place (Table 2). The cells are plated on 60mm culture plates after transfection in antibiotic 
free media. The cells are allowed to grow overnight before media is replaced with media 
treated with neomycin (G418) as a selection process. The cell media was changed regularly 
and the cells were passaged when needed. Further selection was made using Bio-rad cell 
sorter to select for cells expressing the red florescent protein mKate2.  
REAL-TIME PCR 
 
Separate 10cm culture plates were prepared for RNA collection for the LN229 
untreated cells and the LN229 cells that were transfected with the recombinant fusion 
protein. Cells were  lysed with RLT lysis buffer and the RNA was purified from each sample 
using the RNAeasy mini kit (Qiagen, Valencia, CA). cDNA was synthesized using AMV 
reverse transcriptase (Promega Cat. #M5101).  The real-time PCR (rt-PCR) reaction was 
performed using SYBR green mastermix. The 19μl of the PCR master mix (SYBR green, 
primers, dH2O) was loaded into the 48-well plate with 1μl of cDNA sample. The reaction 
was perfomed by using an Applied Biosciences StepOnePlus thermocycler and was 
programed to begin with 1 cycle at 95°C for 10 minutes and then 40 cycles of 15 seconds at 
95°C for denaturing, decreased to annealing temperature of 55°C for 1 minute, and 
increased for elongation at 73°C for 30 seconds.  
The threshold cycle (Ct) was calculated using an automatic baseline and were 
exported to excel. The gene expression was analyzed using a comparative Ct method. This 
method involves normalization to a housekeeping gene, in this case Gyceraldehyde-3-
phosphate dehydrogenase (GAPDH), to calculate a delta Ct. The delta Ct of the transformed 
cell line with the basigin-3 overexpression is then compared to the delta Ct of the untreated 
cell line to get the delta delta Ct. Fold change is calculated by 2^(-delta delta Ct). Fold 
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change indicates  if there is any change in gene regulation. A fold change above one 









































TRANSFECTION OF THE EXPRESSION PLASMIDS RESULTED IN THE SUCESSFUL 
TRANSLATION OF THE MKATE2 PROTEIN.  
 
 The plasmids were confirmed for successful insertion of the basigin-3 construct 
(Figure 1) using a double digestion with mlu1 and sgf1 endonucleases. The basigin-3 insert 
was ligated into the mKate2 expression vector using PCR primers with endonuclease sites 
cloned into the end of the basigin-3 sequence. The double digestion confirmed that three of 
the ligations had basigin-3 construct successfully inserted (Figure 2).   
LN229 GBM and MSU1.1 fibroblast cell lines were cultured to confluency and 
100,000 were transfected with either the mKate2 or the Basigin-3/mKate2 fusion protein 
expression vector (Figure 1) using the Neon transfection system. Transfected cells were 
cultured with the antibiotic neomycin to maintain selection for cells containing the 
recombinant plasmid for the remainder of the project. Flow cytometry and confocal 
imaging was used to confirm successful transfection and that there was successful 
translation of the mKate2 protein in vivo. Flow cytometry was performed using a BioRad 
(Hercules, CA) Cell sorter. Shown in Figure 3A and D are the untransfected LN229 and 
MSU1.1, respectively,  cell count verses the fluorescence of mKate2 protein (left) and the 
size of the cells verses the fluorescence (right).  These readings were used to gate the 
baseline fluorescence seen in the cells. In Figure 3B, E show the LN229 and MSU1.1 cells 
that were transfected with an expression vector with only mKate2. The plots show a 
distinct shift to the right indicating that there is an increase in red fluorescence, therefore 
the cells have been successfully transfected and mKate2 is being translated. The cells that 
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were transfected with the basigin-3 mKate2 construct also show a shift to the right (Figure 
3C, G) indicating successful translation of the basigin-3 mKate2 fusion protein.  
The confocal images of the transfected cells (figure 4) also confirm that the cells 
were successfully transfected and the mKate2 was being translated in vivo. Consistent with 
the flow cytometry results the cells transfected with mKate2 only plasmid (center) is 
expressing more fluorescence than the cells transfected with the basigin-3 mKate2 
construct (right). Figure 5 shows separated panels of the LN229 cells transfected with the 
basigin-3 mKate2 construct. The positive red fluorescence confirms again that the mKate2 
protein is being successfully translated within the fusion protein construct. The cells seem 
to be smaller than usual and unfortunately are not in a good enough shape to see the 
subcellular localization of the fusion protein. 
 
EXPRESSION OF BASIGIN-3 IN LN229 GLIOBLASTOMA CELL LINE 
 
 A PCR reaction with basigin-3 specific primers was run to examine if there is 
normally basigin-3 expressed in the LN229 GBM line. The middle lane is from the LN229 
control sample and the lane on the right is from the LN229 sample transfected with the 
basigin-3 mKate2 expression vector. The positive bands indicate that there is basigin-3 
present in both samples and implies that basigin-3 is normally expressed in the LN229 






mRNA EXPRESSION OF MATRIX MALLOPROTEINASE PROTEINS IN BASIGIN-3 
OVEREXPRESSED CELLS 
 To examine if there are any changes in MMP expression when basigin-3 is 
overexpressed quantitative real-time PCR was ran on RNA isolated from the LN229 cells 
transfected with the basigin-3 mKate2 expression vector (Figure 6). These results were 
averaged from seven replicates of each target gene. Basigin-3 was show at a 1.3 fold change 
compared to control LN229 cells, a lower expression change than expected. None of the 
MMP genes we targeted (MMP1, MMP2, and MMP3) showed a decrease in expression in the 





























 Construction and overexpression of the basigin-3/mKate2 fusion protein in the 
LN229 GBM cell line was performed successfully.  Analysis of the fusion protein expression 
using both flow cytometry and confocal microscopy demonstrated that the fusion protein 
was translated within the cells. Unfortunately, the image quality from the confocal images 
did not allow for any conclusions to be made on the subcellular localization of basigin-3 in 
the cells. The results are consistent with the Liao et al., 2011 paper were the authors  
indicated that basigin-3 is expressed on the cell surface (Liao et al., 2011).  
 One of the proposed functions of basigin-3 is that it has an inhibitory effect on 
basigin-2 (EMMPRIN) function and could inhibit the basigin-2 mediated expression of 
MMPs. In this study, the evidence that suggests the overexpression of basigin-3 does not 
decrease the expression of MMP1, MMP2, or MMP3 in GBM cell lines. In fact, it appears that 
MMP2 expression is increased in the cells expressing the basigin-3/mKate2 fusion protein. 
Additional experiments would need to be performed in order to place any statistical 
significance to this assertion.  
There are several possible explanations for these results. First, it is possible that the 
presence of the mKate2 red fluorescent fusion protein on the carboxy terminus of the 
basigin-3 sequence altered the signaling function of the basigin-3 protein. In order to test 
this, future work using overexpression of un-tagged basigin-3 might rule out this 
possibility. Secondly, the promoter driving expression of the basigin-3/mKate2 fusion 
might not drive expression at a high enough level to produce changes in MMP gene 
expression. In addition, the MMPs that might be responsive to basigin-3 overexpression in 
GBM cells may not be MMP-1, -2, or -3. The hepatocarcinoma cells used in the Liao et al. 
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paper are fundamentally different than GBM cells in their origin and cellular location. Thus, 
it is difficult to know whether this is an inherent limitation of the GBM model being used 
without further information on the expression of MMPs in GBM cells.  
Finally, it is difficult to interpret the results without a more detailed analysis of the 
interactions between basigin-2 and basigin-3 at the plasma membrane of the cell. The 
results of this study cannot rule out the possibility that the overexpressed basigin-
3/mKate2 construct did not physically interact with basigin-2 (EMMPRIN) at the plasma 
membrane. Confirmation of such a protein interaction at the plasma membrane requires 
the use of Forster Resonance Energy Transfer (FRET) methodologies using the basigin-2 
and basigin-3 proteins expressed as recombinant fusion proteins. This work was initiated 
but not completed due to time constraints. However, the initial work of creating and 
characterizing the basigin-2 and basigin-3 FRET vectors is described in Appendix B.  
This study was the first to test the function of basigin-3 overexpression in GBM cell 
line. Like most scientific work, this study has raised more questions than it has answered. 
For example, if the overexpressed basigin-3 protein does have an effect upon cell growth, 
what are these effects? Several possibilities include changes in the ability of the cells to 
grow under varying oxygen or glucose levels, or changes in gene expression other than 
MMP-1, -2, or -3. According to the published literature on basigin-3, this isoform is 
expressed at low levels in normal tissue types. If the observation that basigin-3 expression 
is elevated in GBM cell lines, this protein would still make an interesting target to study for 
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Figure 1.  Basigin-3 mKate2 fusion protein plasmid map.  Construct was designed 

















Figure 2. Double digest with mlu1 and sgf1 to confirm successful 
insertion of Basigin-3 into the plasmid constructs. From left to right: 
Ladder, plasmid single cut sgf1, Basigin-3 PCR product, plasmid single cut 
mlu1, double digested ligation 1, ligation 2, ligation 3, ligation 4, ligation 5, 








    
    









Figure 3. Cell sorter flow cytometry charts confirming successful transfection of 
both LN229 and MSU1.1 cell types. The graphs on the left of each segment are  a cell 
count vs.  fluorescence and the graphs on the right are cell size vs.  fluorescence.  (A) 
LN229 GBM control cells. (B) LN229 +mKate2, cells were transfected with a plasmid 
containing the mKate2 sequence. (C) LN229 + BSG3/mKate2 construct cells that were 
transfected with the recombinant fusion construct of Baigin-3 mKate2. (D) MSU1.1 
fibroblast control cells. (E) MSU1.1 + mKate2, cells were transfected with a plasmid 
containing the mKate2 sequence. (F) MSU1.1 + BSG3/mKate2 construct cells that were 






 Figure 4. Confocal images of LN229 cell line. From left to right: nontransfected LN229, 
transfected with with the mKate2 only plasmid, transfected with the Basigin-3 mKate2 








Figure 5. Confocal images of Basigin-3 expression in LN229 cells. Top left to right: 
DAPI (blue), lipophilic dye (green), mKate expression (red). Bottom left to right: 









Figure 6. Basigin-3 expression in LN229 GBM cell line. A PCR reaction amplifying 
basigin-3 in LN229 control cells (left) and the LN229 cells transfected with the basigin-3 

















Figure 7.  Basigin-3 overexpression does not decrease MMP-1/2/3 
expression in LN229 cells. qRT-PCR results support that the increased 































MSU1.1 1650 20 1 5x106 92 90 
LN229 1300 30 1 5x106 70 70 
 
Table 1: Primer sequences 











Amplification and addition of restriction 







Amplification and addition of restriction 







Amplification and addition of restriction 










































 Basigin-3 MMP1 MMP2 MMP3 
Number of values 7 7 8 7 
          
Minimum 0.1923 0.1701 1.060 0.1851 
25% Percentile 0.1923 0.1701 1.060 0.1851 
Median 1.139 2.367 1.683 0.3175 
75% Percentile 2.301 2.450 5.530 4.382 
Maximum 2.301 2.450 6.812 4.382 
          
Mean 1.367 1.775 2.732 1.441 
Std. Deviation 0.9558 1.097 2.535 2.010 
Std. Error 0.3613 0.4146 0.8963 0.7597 
          
Lower 95% CI of mean 0.4826 0.7604 0.6121 -0.4179 
Upper 95% CI of mean 2.251 2.789 4.851 3.300 
          
One sample t test         
Theoretical mean 1.000 1.000 1.000 1.000 
Actual mean 1.367 1.775 2.732 1.441 
Discrepancy -0.3665 -0.7748 -1.732 -0.4409 
95% CI of discrepancy -0.5175 to 1.251 -0.2396 to 1.789 -0.3882 to 3.851 -1.418 to 2.300 
t, df t=1.015 df=6 t=1.869 df=6 t=1.932 df=7 t=0.5804 df=6 
P value (two tailed) 0.3494 0.1108 0.0947 0.5828 
Significant (alpha=0.05)? No No No No 
 
Table 3: Column statistics of qPCR results.  
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APPENDIX B: FRET VECTORS 
 
HYPOTHESIS AND SPECIFIC AIMS 
 
Hypothesis 2: Basigin-3 interacts with basigin-2 (EMMPRIN) in GBM cell lines 
Aim 2: Examine the protein interactions between basigin-3 and basigin-2 in GBM tumors 





The plasmids were purchased from Addgene, mCerulean N1 was a gift from Steven 
Vogel (Addgene plasmid # 27795), and mVenus N1 was a gift from Steven Vogel (Addgene 
plasmid # 27793). The mCerulean and mVenus (FRET vectors) were transformed into E. 
coli bacteria and plated with Kanamycin.  
 
Bacteria colonies were allowed to grow overnight before a single colony from each 
plate was selected and used to inoculate 5mL of LB broth for amplification. After the 
confirmation of bacteria growth from the small amplifications the 5mL vials were used to 
inoculate 100mL LB broth for large scale amplification. For all amplifications the LB broth 
was kept at 37̊C on a shaker.  
 
Plasmids were purified from the bacteria using Qiagen Plasmid mini and maxi kits 
(Valencia, CA).  After purification a nanodrop was used to measure DNA concentration. 
Restriction enzymes and gel electrophoresis were used to verify plasmid identity. The 
restriction enzymes EcoR1 and BamH1 were used for the FRET vectors.  
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SUBCLONING OF FRET VECTORS 
 
The basigin-3 and basigin-2 insert was amplified using high fidelity Phusion DNA 
polymerase purchased from ThermoFisher (Waltham MA). Primers were designed to clone 
in restriction sites on the gene inserts in order to preferentially clone the genes in correct 
orientation for the FRET expression vectors. Primer information can be found in Table 1. 
Once the gene inserts were amplified by PCR, the ends were digested with the appropriate 
restriction enzymes. The gene inserts were verified and purified through gel 
electrophoresis. The digested PCR product band was cut out of the agrose gel and purified 
using QIAquick gel extraction kit purchased from Qiagen (Valencia, CA). The mKate2 
expression vector was digested using EcoR1 and BamH1 and was also purified through gel 
electrophoresis.  
 
The basigin-3 gene insert and the basigin-2 gene insert were ligated into each of the 
FRET expression vectors (mCreulean and mVenus) using New England BioLab’s Quick 
Ligation Kit (Cat. #M2200S). The ligation product was transformed into E. coli bacteria and 
incubated in 500μl of growth media for 45 minutes. The transformed bacteria was then 
plated on LB agar plates treated with ampicillin and incubated overnight at 37̊C. Single 
colonies were chosen and amplified in 5mL of LB broth.  
 
The plasmids of the amplified bacteria were purified using Qiagen plasmid mini kits 
(Valencia, CA).  The plasmids were verified for successful ligation by PCR using Crimson 
Taq Polymerase and ran through gel electrophoresis. The plasmids with the correct clones 
are further amplified and purified for transfection. The plasmids where confirmed for 
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successful insertion of the basigin-3 construct (App. Figure 1) using a double digestion with 
mlu1 and sgf1 endonucleases. The basigin-3 insert was ligated into the FRET expression 
vectors using PCR primers with endonuclease sites cloned into the end of the basigin-3 
sequence. The double digestion confirmed that three of the ligations had basigin-3 or 
basigin-2 constructs successfully inserted (App. Figure 2).  Ligation 3-2 (mVenus+basigin-
2), Ligation 4-2 and 4-5 (mCerulean+basigin-2), Ligation 5-2 (mVenus+Basigin-3), and 
Ligation 6-5 (mCerulean-Basigin-3) all showed successful inserts from either the double 

























Appendix Figure 1. FRET plasmid maps. A plasmid was created in order for there to be 










Appendix Figure 2. Double digest and PCR results. A.  Shows the double digest results 
for the ligation 3 and 4. From the left: Ladder, uncut plasmid, cut plasmid, EMMPRIN PCR 
product, BSG3 PCR product, Ligation 3 (1-5), ligation 4 (1-4). From this gel you can see 
that ligation 3-2 and ligation 4-2 run smaller than the other cut plasmids, suggesting that 
there might be a successful insert of the EMMRIN construct. B.  Shows the PCR results 
when Ligation 4-2 and 4-5, ligation 5- 2, and ligation 6-5 were targeted for their 
respected EMMPRIN or BSG3 inserts. All of the samples came back positive for the insert.  
